The Top 5 Biosimilar Articles for the Week of June 23

A Promise Unfulfilled: The State of Biosimilars

October 2nd 2024

By Mark Campbell, PharmD

For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.

Biosimilar Policy Roundup—September 2024

October 1st 2024

By Skylar Jeremias

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.

Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

September 30th 2024

By Laura Joszt

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs

September 30th 2024

By Skylar Jeremias

Future Biosimilar Trends, Challenges, and Opportunities

September 29th 2024

By Cameron Santoro

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.

Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study

September 28th 2024

By Deana Ferreri, PhD

A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.

The Top 5 Biosimilar Articles for the Week of September 23

September 27th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of September 23, 2024.

Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing

September 26th 2024

By Skylar Jeremias

The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.

IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share

September 25th 2024

By Skylar Jeremias

The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its impact has been limited due to preexisting competitive market conditions.

AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2

September 24th 2024

By Skylar Jeremias

Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.